Neurothera Labs Company Description

Neurothera Labs Inc. operates a clinical-stage pharmaceutical company.

The company engages in the drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer's disease and agitation; and SCI- 210 for the treatment of ASD and status epilepticus.

Neurothera Labs Inc. was formerly known as Miza III Ventures Inc. The company is based in Vancouver, Canada.

As of February 23, 2023, Neurothera Labs Inc. operates as a subsidiary of SciSparc Ltd.